KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis

Rabara, Dana, Tran, Timothy H., Dharmaiah, Srisathiyanarayanan, Stephens, Robert M., McCormick, Frank, Simanshu, Dhirendra K., Holderfield, Matthew·2019·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.1908353116

Cited by (128)

Items 101–128 of 128

  1. Targeting KRAS for cancer therapy
    Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos · 2026 · British Journal of Pharmacology
  2. Parallel Rap1>RalGEF>Ral and Ras signals sculpt the C. elegans nervous system
    Jacob I. Mardick, Neal R. Rasmussen, Bruce Wightman, David J. Reiner · 2021 · Developmental Biology
  3. NF1 Gene Novel Splicing Mutations in a Chinese Family with Neurofibromatosis Type 1: Case Series
    Ting Wu, Hao Yang, Liuli Xu, Qing Huang, Qi He, RONG TSUN WU, Yunzhu Mu · 2022 · Clinical Cosmetic and Investigational Dermatology
  4. RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors
    Beau Baars, Ana Orive-Ramos, Ziyue Kou, Bijaya Gaire, Mathieu Desaunay, Christos Adamopoulos, Stuart A. Aaronson, Shaomeng Wang, Evripidis Gavathiotis, Poulikos I. Poulikakos · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  5. Harmine suppresses pancreatic cancer through DYRK1A-mediated hyper-activated RAS/MAPK inhibition.
    Cen Liu, Jinchai Qi, Danyang Ye, Shuyue Wang, Jieshu Li, Xiao-Yu Guo, Xia Li, Mei Ding, Yong-Gang Liu · 2025 · Biochemical Pharmacology
  6. Molecular Dynamics Simulations Reveal Structural Interconnections within Sec14-PH Bipartite Domain from Human Neurofibromin
    Fabio Rizza, Jacopo Vertemara, Renata Tisi · 2022 · International Journal of Molecular Sciences
  7. Identification of Altered Primary Immunodeficiency-Associated Genes and Their Implications in Pediatric Cancers
    Shaelene Standing, Son Tran, Luis E. Murguía-Favela, Olga Kovalchuk, Pinaki Bose, Aru Narendran · 2022 · Cancers
  8. The evolution of RAS structural biology
    Dhirendra K. Simanshu, John E. Knox · 2024 · Elsevier eBooks
  9. A cancer-associated K-RAS mutant that preferentially binds GDP displays gain-of-function and atypical signaling
    Xiaolan Qian, Tatu Pantsar, Alex G. Papageorge1, Brajendra K. Tripathi, Beatriz Sánchez‐Solana, Marian E. Durkin, Yucheng Gao, Dominic Esposito, Timothy J. Waybright, Andrew G. Stephen et al. · 2022 · Research Square
  10. Data from Delineating the RAS Conformational Landscape
    Parker, Mitchell I., Meyer, Joshua E., Golemis, Erica A., Dunbrack,, Roland L. · 2023
  11. Genomics-based Precision Medicine for Patients with Cancer
    Joris van de Haar · 2021
  12. The structural basis of allosteric communication networks of Ras GTPases and their oncogenic mutants
    Alicia Yvette Volmar · 2020
  13. Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
    Robert B. Scharpf, Archana Balan, Biagio Ricciuti, Jacob Fiksel, Christopher Cherry, Chenguang Wang, Michele L. Lenoue-Newton, Hira A. Rizvi, James Robert White, Alexander Spyridon Baras et al. · 2023
  14. Data from Delineating the RAS Conformational Landscape
    Parker, Mitchell I., Meyer, Joshua E., Golemis, Erica A., Dunbrack,, Roland L. · 2023
  15. Introduction to RAS biology
    Channing J. Der, Frank McCormick · 2024 · Elsevier eBooks
  16. Cooperativity between Ras pathway mutations in colonic tumorigenesis
    Christian William Johnson, Anna Idelevich, Bing Shui, Alison W. Tisdale, Eve O’Donoghue, Joshua Cook, Shannon Hull, Moon Hee Yang, Shikha Sheth, Elizabeth M. Terrell et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  17. Pathogenic Neurofibromatosis type 1 gene variants in tumors of non‐ NF1 patients and role of R1276
    Mareike Selig, Swanhild Lohse, Sara Elahi, Nils Hartmann, Stefanie Deckert, Shutian Si, Alexander Desuki, Anja Harder · 2025 · FEBS Open Bio
  18. Allosteric prediction via convolutional neural networks and protein structural and dynamical features
    Rajitha Rajeshwar T., John H. Lagergren, Jeremy C. Smith, Omar Demerdash · 2025 · Biophysical Journal
  19. Chronic myelomonocytic leukemia with double activating KRAS mutations: molecular characterization of an uncommon case
    Enderson Murillo Ramos, Carlos Humberto Afanador Ayala, Katherine Andrea Palacio Rúa, Ángela Rodríguez Cárdenas, Gloria Cecilia Ramírez Gaviria, Claudia Marcela Cristancho Salgado, Nora Elena Durango Calle, Danna Cano Granda, Anyeli Hinestroza Cordoba, Juan Carlos Herrera Patiño et al. · 2026 · medRxiv
  20. The Neomorphic Chemistry of KRAS Autophosphorylation Is Dynamically Regulated by Active Site Conformation
    Christian William Johnson, Rofiat Oladimeji, Eve O’Donohue, Kevin M. Haigis · 2026 · ACS Chemical Biology
  21. From undruggable to actionable: advances in KRAS targeting in colorectal cancer
    Mei Chan, Meghna Shelke, Amanda Rose Townsend, Amitesh Chandra Roy, Vy Tuong Broadbridge, Christos Stelios Karapetis, T. J. Price · 2026 · Academia oncology.
  22. Unlocking drug sensitivity in KRAS
    MingCong LI, YueSong ZHOU, Tai Dong Qiao, QingLin BAI, Chuanchuan Li · 2026 · Scientia Sinica Vitae
  23. A catalogue of missense and nonsense mutation abundances for the U.S. cancer patient population
    Adith S. Arun, David Liarakos, Gaurav Mendiratta, Thomas B. McFall, Diana C. Hargreaves, Geoffrey M. Wahl, Jiancheng Hu, Edward C. Stites · 2026 · medRxiv
  24. KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment
    Shikai Jin, Zinan Zhang, Fuchao Liang, Yang Yang, Aiping Lü, Chao Liang · 2026 · Biomarker Research
  25. GDP-Loaded K-Ras Transiently Binds to Effector B-Raf RBD, Mirroring the Structure of the Active GTP-Loaded Complex
    Xinyao Xiang, Mamata Basnet, Chunhua Yuan, Lei Bruschweiler‐Li, Rafael Brüschweiler · 2026 · Journal of the American Chemical Society
  26. Investigating the effects of missense mutations on the dual Ras/Rap activation mechanism of SYNGAP1 using molecular modelling
    Aliaa E. Ali, Arto Liljeblad, Jukka V. Lehtonen, Noboru H. Komiyama, Pekka A. Postila · 2026 · Journal of Structural Biology X
  27. KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
    Jiaying Cai, Yimin Wu, Xing Jia, Li Yang, Wenjun Yang, Weishan Lu, Zhiye Huang, Yang Pan, Zetao Fei, Junnan Ru et al. · 2026 · MedComm
  28. Uncovering KRAS -mutant allele-specific biology and vulnerabilities in non-small cell lung cancer
    Paolo D. d’Arienzo, William J. McDaid, Kirsten L. Tinsley, Tong Chen, Emma J. Gasson, Colin R. Lindsay, Angeliki Malliri · 2026 · Biochemical Journal